Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) reported third quarter 2026 GAAP revenue of $253.7 million, a 177% increase year-over-year, driven by a series of completed acquisitions. The vertically integrated cannabis company announced it has surpassed a $1 billion annualised revenue run rate and closed the quarter with $106.8 million in cash. Investors are closely watching the company's accelerating consolidation strategy, which includes a pending all-stock merger with Planet 13 Holdings and several additional acquisitions expected to lift its dispensary count to approximately 270 across 15 states.

Key Points

  • Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) reported Q3 2026 financial results on November 10, 2026
  • GAAP revenue rose 177% year-over-year to $253.7 million, with Adjusted EBITDA of $42.7 million
  • Q4 2026 revenue guidance of $250–$265 million; Q1 2027 guidance of $280–$300 million
  • Investors may be watching the pending Planet 13 merger, Ohio acquisitions, and Cannabist asset transaction for further scale milestones

Vireo Q3 2026 Revenue and Profitability Performance

GAAP cannabis revenue reached $198.1 million in Q3 2026, up 116% from $91.7 million in Q3 2025, while non-cannabis revenue contributed $55.6 million. GAAP gross profit was $107.8 million, representing a margin of 42.5%, up 170 basis points year-over-year. Adjusted EBITDA of $42.7 million improved 68.1% year-over-year, though the Adjusted EBITDA margin contracted to 16.8% from 27.7% in the prior-year period, reflecting integration costs and margin dilution from newly acquired businesses. Sequentially, GAAP revenue rose 21.2% from Q2 2026's $209.3 million.

Acquisition Activity Reshaping Vireo's Multi-State Footprint

During Q3 2026, Vireo completed the acquisitions of PharmaCann's Colorado retail assets and C21 Investments, adding three Silver State dispensaries in Nevada and approximately 104,000 square feet of cultivation and production capacity. The company also acquired a 49% interest in a joint venture holding a Pennsylvania clinical registrant licence through PhytoNatural. Additionally, Vireo announced agreements to acquire select Cannabist Company assets across Colorado, Illinois, Massachusetts, and New Jersey, and entered an all-stock merger agreement with Planet 13 Holdings, expected to expand its Nevada and Florida platforms.

Balance Sheet Position and New Financing Arrangements

Vireo closed Q3 with $106.8 million in cash and total current assets, excluding income taxes receivable, of $349.0 million. Long-term debt stood at $293 million, with net debt of $186.2 million. During the quarter, the company secured an $85.0 million five-year asset-based revolving credit facility with Bank of Montreal for its non-cannabis agricultural supply business. Subsequent to quarter-end, Vireo announced a $60.0 million real estate term loan at a fixed rate of 8.50%, which refinanced a $49.0 million seller note that had carried a 15% interest rate.

Vireo Issues Q4 2026 and Q1 2027 Financial Guidance

For Q4 2026, Vireo guided revenue of $250 million to $265 million and Adjusted EBITDA of $45 million to $48 million, incorporating FLUENT results from the November 9, 2026 closing date. For Q1 2027, guidance calls for revenue of $280 million to $300 million and Adjusted EBITDA of $53 million to $56 million, including a full quarter of FLUENT. Pending acquisitions not yet closed are excluded from both guidance ranges. The company stated it intends to provide guidance on a sequential, quarterly basis and does not plan to issue full-year guidance at this stage.